ISCHEMIA试验预设分析:初始侵入性与保守管理的存活出院天数比较
该预设分析比较ISCHEMIA试验中5179例稳定冠心病伴中重度缺血患者,随机接受侵入性或保守管理的存活出院天数(DAOH)。保守组在1个月、1年、2年的DAOH更高,但4年时无显著差异;侵入组早期DAOH减少源于方案指定的操作住院,随访中心梗和不稳定心绞痛住院更少。
要点
- 保守管理在前2年DAOH更高,但4年时与侵入管理无显著差异。
- 侵入管理早期DAOH减少主要归因于方案指定的操作住院。
- 侵入管理组随访中心梗和不稳定心绞痛住院更少。
核心结论
- 保守管理组前2年DAOH更高,但4年时两组无显著差异。
- 侵入管理组早期DAOH减少由方案指定操作导致。
- 侵入管理组随访中心梗和不稳定心绞痛住院更少。
研究设计与样本
- ISCHEMIA随机临床试验的预设分析,纳入5179例稳定冠心病伴中重度缺血患者。
- 患者随机分为侵入管理(血管造影及可行血运重建)或保守管理,两组均接受最佳药物治疗。
- 来自37个国家320个中心,数据收集于2012年7月至2019年6月。
主要发现
- 平均DAOH保守组 vs 侵入组:1个月30.8 vs 28.4天(P < .001),1年362.2 vs 355.9天(P < .001),2年718.4 vs 712.1天(P = .001)。
- 4年DAOH两组无显著差异(1415.0 vs 1412.2天;P = .65)。
- 侵入组4002次住院中2434次(60.8%)为方案指定操作。
- 排除方案指定操作后,各时间点DAOH无 clear 差异。
- 随访期间侵入组住院和扩展护理机构停留更多(4002 vs 1897;P < .001);排除方案指定操作后侵入组更少(1568 vs 1897;P = .001)。
临床怎么用
- DAOH可作为以患者为中心的指标,用于稳定冠心病管理的共享决策。
- 临床医生应与患者讨论侵入管理早期住院增加与随访中心血管住院减少的权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Traditional time-to-event analyses rate events occurring early as more important than later events, even if later events are more severe, eg, death. Days alive out of hospital (DAOH) adds a patient-focused perspective beyond trial end points. OBJECTIVE: To compare DAOH between invasive management and conservative management, including invasive protocol-assigned stays, in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified analysis of the ISCHEMIA trial, DAOH was compared between 5179 patients with stable coronary disease and moderate or severe ischemia randomized to invasive management or conservative management. Participants were recruited from 320 sites in 37 countries. Stays included overnight stays in hospital or extended care facility (skilled nursing facility, rehabilitation, or nursing home). DAOH was separately analyzed excluding invasive protocol-assigned procedures. Data were collected from July 2012 to June 2019, and data were analyzed from July 2020 to April 2021. INTERVENTIONS: Invasive management with angiography and revascularization if feasible or conservative management, with both groups receiving optimal medical therapy. MAIN OUTCOMES AND MEASURES: The hypothesis was formulated before data lock in July 2020. The primary end point was mean DAOH per patient between randomization and 4 years. Initial stays for invasive protocol-assigned procedures were prespecified to be excluded. RESULTS: Of 5179 included patients, 1168 (22.6%) were female, and the median (interquartile range) age was 64 (58-70) years. The average DAOH was higher in the conservative management group compared with the invasive management group at 1 month (30.8 vs 28.4 days; P < .001), 1 year (362.2 vs 355.9 days; P < .001), and 2 years (718.4 vs 712.1 days; P = .001). At 4 years, the 2 groups' DAOH were not significantly different (1415.0 vs 1412.2 days; P = .65). In the invasive management group, 2434 of 4002 stays (60.8%) were for protocol-assigned procedures. There were no clear differences at any time point in DAOH when protocol-assigned procedures were excluded from the invasive management group. There were more hospital and extended care stays in the invasive management vs conservative management group during follow-up (4002 vs 1897; P < .001). Excluding protocol-assigned procedures, there were fewer stays in the invasive vs conservative group (1568 vs 1897; P = .001). Cardiovascular stays following the initial assigned procedures were lower in the invasive management group (685 of 4002 [17.1%] vs 1095 of 1897 [57.8%]; P < .001) due to decreased spontaneous myocardial infarction stays (65 [1.6%] vs 123 [6.5%]; P < .001) and unstable angina stays (119 [3.0%] vs 216 [11.4%]; P < .001). CONCLUSIONS AND RELEVANCE: DAOH was higher for patients in the conservative management group in the first 2 years but not different at 4 years. DAOH was decreased early in the invasive management group due to protocol-assigned procedures. Hospital stays for myocardial infarction and unstable angina during follow-up were lower in the invasive management group. DAOH provides a patient-focused metric that can be used by clinicians and patients in shared decision-making for management of stable coronary artery disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01471522.
引用
- White HD, O'Brien SM, Alexander KP, et al. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiol. 2021. PMID: 33938917. doi:10.1001/jamacardio.2021.1651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。